Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Phase IIb Trial of Telbivudine (LdT) Versus the Combination of Telbivudine and Valtorcitabine (Val-LdC) in Patients With Chronic Hepatitis B

NCT00128544 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00128544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00128544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Phase IIb Trial of Telbivudine (LdT) Versus the Combination of Telbivudine and Valtorcitabine (Val-LdC) in Patients With Chronic Hepatitis B
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2005
Completion date
May 31, 2007
Enrollment
130
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b